UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

A Review of the Pharmacokinetics of Abacavir

Clinical pharmacokinetics, 2008-01, Vol.47 (6), p.351-371

2008

Link zum Volltext

Verfügbarkeit prüfen

Steady-State Pharmacokinetics of Abacavir in Plasma and Intracellular Carbovir Triphosphate following Administration of Abacavir at 600 Milligrams Once Daily and 300 Milligrams Twice Daily in Human Immunodeficiency Virus-Infected Subjects

Antimicrobial Agents and Chemotherapy, 2009-04, Vol.53 (4), p.1532-1538

2009

Link zum Volltext

Verfügbarkeit prüfen

Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams Once Daily and 150 Milligrams Twice Daily

Antimicrobial Agents and Chemotherapy, 2004-01, Vol.48 (1), p.176-182

2004

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects

Antimicrobial Agents and Chemotherapy, 2008-02, Vol.52 (2), p.534-538

2008

Link zum Volltext

Verfügbarkeit prüfen

A Preliminary Evaluation of Nelfinavir Mesylate, an Inhibitor of Human Immunodeficiency Virus (HIV)-1 Protease, to Treat HIV Infection

The Journal of infectious diseases, 1998-06, Vol.177 (6), p.1533-1540

1998

Link zum Volltext

Verfügbarkeit prüfen

Short-Term Measures of Relative Efficacy Predict Longer-Term Reductions in Human Immunodeficiency Virus Type 1 RNA Levels following Nelfinavir Monotherapy

Antimicrobial Agents and Chemotherapy, 2001-05, Vol.45 (5), p.1438-1443

2001

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials

Antimicrobial Agents and Chemotherapy, 1999-12, Vol.43 (12), p.3025-3029

1999

Link zum Volltext

Verfügbarkeit prüfen

Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men

Journal of acquired immune deficiency syndromes (1999), 2008-06, Vol.48 (2), p.156

2008

Link zum Volltext

Verfügbarkeit prüfen

Once-Daily Quadruple-Drug Therapy with Adefovir Dipivoxil, Lamivudine, Didanosine, and Efavirenz in Treatment-Naive Human Immunodeficiency Virus Type 1–Infected Patients

The Journal of infectious diseases, 2002-10, Vol.186 (7), p.1028-1033

2002

Link zum Volltext

Verfügbarkeit prüfen

Serum and Cerebrospinal Fluid Pharmacokinetics of Intravenous and Oral Lamivudine in Human Immunodeficiency Virus-Infected Children

Antimicrobial Agents and Chemotherapy, 1998-12, Vol.42 (12), p.3187-3192

1998

Link zum Volltext

Verfügbarkeit prüfen

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents

Journal of acquired immune deficiency syndromes (1999), 2009-05, Vol.51 (1), p.54

2009

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end‐stage renal failure

British journal of clinical pharmacology, 2007-12, Vol.64 (6), p.738-744

2007

Link zum Volltext

Verfügbarkeit prüfen

A Comparison of the Steady-State Pharmacokinetics and Safety of Abacavir, Lamivudine, and Zidovudine Taken as a Triple Combination Tablet and as Abacavir plus a Lamivudine-Zidovudine Double Combination Tablet by HIV-1-Infected Adults

Pharmacotherapy, 2001-04, Vol.21 (4), p.424-430

2001

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study

Blood, 2015-12, Vol.126 (23), p.4836-4836

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical pharmacokinetics of lamivudine

Clinical pharmacokinetics, 1999, Vol.36 (1), p.41-66

1999

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction

Antimicrobial Agents and Chemotherapy, 1996-06, Vol.40 (6), p.1514-1519

1996

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole

Clinical pharmacology and therapeutics, 1996-05, Vol.59 (5), p.550-558

1996

Link zum Volltext

Verfügbarkeit prüfen

Prospective use of optimal sampling theory: Steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients

Clinical pharmacology and therapeutics, 1989-10, Vol.46 (4), p.451-457

1989

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection

The Journal of infectious diseases, 1995-06, Vol.171 (6), p.1438

1995

Link zum Volltext

Verfügbarkeit prüfen

Abacavir/Lamivudine/Zidovudine As a Combined Formulation Tablet: Bioequivalence Compared with Each Component Administered Concurrently and the Effect of Food on Absorption

Journal of clinical pharmacology, 2001-03, Vol.41 (3), p.277-288

2001

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, Absolute Bioavailability, and Absorption Characteristics of Lamivudine

Journal of clinical pharmacology, 1995-12, Vol.35 (12), p.1174-1180

1995

Link zum Volltext

Verfügbarkeit prüfen

Altered Pharmacokinetics in the Elderly

Clinics in geriatric medicine, 1990-05, Vol.6 (2), p.257-267

Yuen, Geoffrey J.

1990

Link zum Volltext

Verfügbarkeit prüfen

Abacavir/Lamivudine/Zidovudme As a Combined Formulation Tablet: Bioequivalence Compared with Each Component Administered Concurrently and the Effect of Food on Absorption

Journal of clinical pharmacology, 2001-03, Vol.41 (3), p.277-288

2001

Link zum Volltext

Verfügbarkeit prüfen

Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial

Annals of internal medicine, 1992-04, Vol.116 (7), p.562

1992

Link zum Volltext

Verfügbarkeit prüfen

A Preliminary Evaluation of Nelfinavir Mesylate, an Inhibitor of Human Immunodeficiency Virus (HIV)-l Protease, to Treat HIV Infection

The Journal of infectious diseases, 1998-06, Vol.177 (6), p.1533-1540

1998

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(39)

Publikationsform

Sprache

Englisch
(54)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(39)
Science & Technology
(38)
Life Sciences & Biomedicine
(37)
Biological And Medical Sciences
(31)
Medical Sciences
(31)
Male
(25)
Pharmacology. Drug Treatments
(25)
Adult
(22)
Female
(21)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(20)
Pharmacology & Pharmacy
(19)
Middle Aged
(17)
Antiviral Agents
(16)
Microbiology
(15)
Adolescent
(11)
Aids/hiv
(11)
Infectious Diseases
(11)
Anti-Hiv Agents - Pharmacokinetics
(10)
Pharmacokinetics
(10)
Human Immunodeficiency Virus
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Review of the Pharmacokinetics of Abacavir

Steady-State Pharmacokinetics of Abacavir in Plasma and Intracellular Carbovir Triphosphate following Administration of Abacavir at 600 Milligrams Once Daily and 300 Milligrams Twice Daily in Human Immunodeficiency Virus-Infected Subjects

Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams Once Daily and 150 Milligrams Twice Daily

Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects

A Preliminary Evaluation of Nelfinavir Mesylate, an Inhibitor of Human Immunodeficiency Virus (HIV)-1 Protease, to Treat HIV Infection

Short-Term Measures of Relative Efficacy Predict Longer-Term Reductions in Human Immunodeficiency Virus Type 1 RNA Levels following Nelfinavir Monotherapy

Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials

Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men

Once-Daily Quadruple-Drug Therapy with Adefovir Dipivoxil, Lamivudine, Didanosine, and Efavirenz in Treatment-Naive Human Immunodeficiency Virus Type 1–Infected Patients

Serum and Cerebrospinal Fluid Pharmacokinetics of Intravenous and Oral Lamivudine in Human Immunodeficiency Virus-Infected Children

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents

Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end‐stage renal failure

A Comparison of the Steady-State Pharmacokinetics and Safety of Abacavir, Lamivudine, and Zidovudine Taken as a Triple Combination Tablet and as Abacavir plus a Lamivudine-Zidovudine Double Combination Tablet by HIV-1-Infected Adults

Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study

Clinical pharmacokinetics of lamivudine

Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction

Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole

Prospective use of optimal sampling theory: Steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection

Abacavir/Lamivudine/Zidovudine As a Combined Formulation Tablet: Bioequivalence Compared with Each Component Administered Concurrently and the Effect of Food on Absorption

Pharmacokinetics, Absolute Bioavailability, and Absorption Characteristics of Lamivudine

Altered Pharmacokinetics in the Elderly

Abacavir/Lamivudine/Zidovudme As a Combined Formulation Tablet: Bioequivalence Compared with Each Component Administered Concurrently and the Effect of Food on Absorption

Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial

A Preliminary Evaluation of Nelfinavir Mesylate, an Inhibitor of Human Immunodeficiency Virus (HIV)-l Protease, to Treat HIV Infection

Suchergebnisse filtern